索拉菲尼与卡培他滨对晚期肝细胞癌患者化疗的对比分析  

Differences analysis of sorafenib and capecitabine for advanced hepatocarcinoma

作　　者：刘小红[1] 赵磊[1] 吕西[1] 曾祥挺[1] 贺东强[1] 宋爱琳[1] 

机构地区：[1]兰州大学第二医院普外科,甘肃兰州730030

出　　处：《兰州大学学报（医学版）》2015年第1期50-54,共5页Journal of Lanzhou University（Medical Sciences）

基　　金：甘肃省自然科学基金项目(1107RJZA186)

摘　　要：目的比较索拉菲尼与卡培他滨在治疗晚期肝细胞癌中的安全性与有效性。方法回顾性分析2009年1月-2011年1月收治并确诊的晚期不能手术的肝细胞癌患者36例,口服索拉菲尼组18例,口服卡培他滨组18例,观察2种化疗方案对晚期肝细胞癌患者短期疗效、远期疗效以及毒副反应。结果短期疗效分析,索拉菲尼组和卡培他滨组的疾病控制率之间差异无统计学意义。远期疗效分析,索拉菲尼的无进展生存期和总生存期分别为8.265个月和9.539个月,明显高于卡培他滨组的无进展生存期(5.367个月)和总生存期(6.188个月),P<0.05,差异有统计学意义。索拉菲尼组的血小板减少以及肝功能异常出现率明显低于卡培他滨组(P<0.05),其他反应2组之间差异无统计学意义。结论在治疗晚期肝细胞癌时,卡培他滨与索拉非尼相比,疗效较低,且有较大的毒副反应,因而临床上应该推荐索拉非尼。Objective Explore the difference of safety and effect between sorafenib and capecitabine in ad- vanced hepatocarcinoma. Methods Retrospectively analyze the advanced inoperable hepatocarcinoma pa- tients from January 2009 to January 2011 in our hospital that include 18 patients with oral sorafenib or capeeitabine and analyze the difference of short-term effect, long-term effect and toxicity between two groups. Results The disease control rate of sorafenib was higher than capecitabine groups, without statistical significance; long-term effect： the progression free survival and overall survival of sorafenib respectively were 8.265 months and 9.539 months which were higher than capecitabine groups （5.367 months and 6.188 months）, P 〈 0.05, the difference has statistically significant; toxicity： the rate of thrombocytopenia and dys- function of liver of sorafenib were significant lower than those of capecitabine （ P 〈 0.05）. Conclusion Sorafenib has a better effect and lower toxicity compared capecitabine for advanced hepatocarcinoma, so it can be used as an effective choice in clinic.

关 键 词：索拉菲尼 卡培他滨 晚期肝细胞癌 化疗 

分 类 号：R735.7[医药卫生—肿瘤]